ModernGraham Valuation

Company Name:

Zoetis Inc

Company Ticker ZTS

Date of Analysis

10/28/2015



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

 Adequate Size of the Enterprise 	Market Cap > \$2Bil	\$21,344,560,102 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	2.11 Pass
3. Earnings Stability	Positive EPS for 10 years prior	Fail
4. Dividend Record	Dividend Payments for 10 years prior	Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at	
5. Earnings Growth	beginning and end	10600.00% Pass
6. Moderate PEmg Ratio	PEmg < 20	43.05 Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	18.43 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	2.11 Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	1.86 Fail
3. Earnings Stability	Positive EPS for 5 years prior	Pass
4. Dividend Record	Currently Pays Dividend	Pass
5. Earnings Growth	EPSmg greater than 5 years ago	Pass

Suitability

Defensive No Enterprising Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$1.01
MG Growth Estimate	15.00%
MG Value	\$38.76
MG Value based on 3% Growth	\$14.60
MG Value based on 0% Growth	\$8.56
Market Implied Growth Rate	17.28%

MG Opinion

Current Price \$43.34 % of Intrinsic Value 111.83%

Opinion Overvalued

Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$4.21
Graham Number	\$7.43
PEmg	43.05
Current Ratio	2.11
PB Ratio	18.43
Dividend Yield	0.72%
Number of Consecutive Years of Dividend Growth	3


Morningstar

Useful Links: ModernGraham tagged articles

Google FinanceMSN MoneyYahoo FinanceSeeking AlphaGuruFocusSEC Filings

EPS History		EPSmg History		
Next Fiscal Year Estimate	\$1.04	Next Fiscal Year Estimate		\$1.01
Dec14	\$1.16	Dec14		\$0.91
Dec13	\$1.01	Dec13		\$0.70
Dec12	\$0.87	Dec12		\$0.46
Dec11	\$0.49	Dec11		\$0.22
Dec10	\$0.22	Dec10		\$0.07
Dec09	\$0.00	Dec09		\$0.00
Dec08	\$0.00	Dec08		\$0.00
Dec07	\$0.00	Dec07		\$0.00
Dec06	\$0.00	Dec06		\$0.00
Dec05	\$0.00	Dec05		\$0.00
Dec04	\$0.00	Dec04		\$0.00
Dec03	\$0.00	Dec03		\$0.00
Dec02	\$0.00	Dec02		\$0.00
Dec01	\$0.00	Dec01		\$0.00
Dec00	\$0.00	Dec00		\$0.00
Dec99	\$0.00	Dec99		\$0.00
Dec98	\$0.00	Balance Sheet Information	Jun15	
Dec97	\$0.00	Total Current Assets		\$3,316,000,000
Dec96	\$0.00	Total Current Liabilities		\$1,572,000,000
Dec95	\$0.00	Long-Term Debt		\$3,243,000,000
		Total Assets		\$6,598,000,000
		Intangible Assets		\$1,864,000,000
		Total Liabilities		\$5,422,000,000
		Shares Outstanding (Diluted Average)		500,173,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company The Best Companies of the Pharmaceuticals Industry – August 2015

The 16 Best Stocks For Value Investors This Week – 8/1/15

Zoetis Inc. Analysis – July 2015 Update \$ZTS

 $\underline{\mbox{27 Companies in the Spotlight This Week}-4/4/15}$

Zoetis Inc. Quarterly Valuation - March 2015 \$ZTS

Other ModernGraham posts about related companies Biogen Inc. Valuation – October 2015 Update \$BIIB

Perrigo Company PLC Analysis - October 2015 Update \$PRGO

Amgen Inc. Analysis – September 2015 Update \$AMGN

Pfizer Inc Analysis – September 2015 Update \$PFE

Johnson & Johnson Analysis – September 2015 Update \$JNJ

Celgene Corporation Analysis – September 2015 Update \$CELG

Allergan PLC Analysis – August 2015 Update \$AGN

The Best Companies of the Pharmaceuticals Industry – August 2015

Alexion Pharmaceuticals Inc. Analysis – August 2015 Update \$ALXN

Akorn Inc. Analysis – Initial Coverage \$AKRX